PLoS ONE, ISSN 1932-6203, 04/2016, Volume 11, Issue 4, p. e0153243
World Health Organization advocates for integration of HIV-tuberculosis (TB) services and recommends intensive case finding (ICF), isoniazid preventive therapy...
South America | Poverty | World Health Organization | Humans | AIDS-Related Opportunistic Infections - drug therapy | Africa | Infection Control | AIDS-Related Opportunistic Infections - diagnosis | Caribbean Region | Tuberculosis - diagnosis | AIDS-Related Opportunistic Infections - prevention & control | Asia | Tuberculosis - drug therapy | Tuberculosis - prevention & control | HIV Infections - complications | HIV Infections - drug therapy | Isoniazid - therapeutic use | Antitubercular Agents - therapeutic use | Prevention | Complications and side effects | Usage | Tuberculosis | Dosage and administration | Research | Diagnosis | Drug therapy | Medicine, Preventive | Isoniazid | Preventive health services | Health care | Medical personnel | Therapy | Integration | Income | Infections | Tuberculin | Preventive medicine | Medical diagnosis | Patients | Masks | Studies | Screening | Acquired immune deficiency syndrome--AIDS | Workers | Collaboration | Human immunodeficiency virus--HIV | Smear | Occupational health | Skin | Skin tests | Acquired immune deficiency syndrome | AIDS | HIV | Human immunodeficiency virus
South America | Poverty | World Health Organization | Humans | AIDS-Related Opportunistic Infections - drug therapy | Africa | Infection Control | AIDS-Related Opportunistic Infections - diagnosis | Caribbean Region | Tuberculosis - diagnosis | AIDS-Related Opportunistic Infections - prevention & control | Asia | Tuberculosis - drug therapy | Tuberculosis - prevention & control | HIV Infections - complications | HIV Infections - drug therapy | Isoniazid - therapeutic use | Antitubercular Agents - therapeutic use | Prevention | Complications and side effects | Usage | Tuberculosis | Dosage and administration | Research | Diagnosis | Drug therapy | Medicine, Preventive | Isoniazid | Preventive health services | Health care | Medical personnel | Therapy | Integration | Income | Infections | Tuberculin | Preventive medicine | Medical diagnosis | Patients | Masks | Studies | Screening | Acquired immune deficiency syndrome--AIDS | Workers | Collaboration | Human immunodeficiency virus--HIV | Smear | Occupational health | Skin | Skin tests | Acquired immune deficiency syndrome | AIDS | HIV | Human immunodeficiency virus
Journal Article
PLoS ONE, ISSN 1932-6203, 06/2013, Volume 8, Issue 6, p. e66135
Background: HIV-2 is endemic in West Africa. There is a lack of evidence-based guidelines on the diagnosis, management and antiretroviral therapy (ART) for...
HIV-2-INFECTED INDIVIDUALS | INTERNATIONAL COLLABORATION | RALTEGRAVIR | MULTIDISCIPLINARY SCIENCES | IMMUNOLOGICAL RESPONSE | INFECTION | DRUG-RESISTANCE | TYPE-1 HIV-1 | DIFFERENTIATION | INHIBITORS | TO-CHILD TRANSMISSION | Africa, Western - epidemiology | HIV-1 - isolation & purification | HIV-2 - isolation & purification | HIV Infections - virology | Humans | Middle Aged | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | Male | Cohort Studies | Infection | Antiviral agents | Highly active antiretroviral therapy | Analysis | HIV (Viruses) | Health aspects | Evidence-based medicine | Epidemiology | Medical research | Antiretroviral drugs | Therapy | Clinical trials | Infections | Medical diagnosis | Patients | Antiretroviral therapy | CD4 antigen | Acquired immune deficiency syndrome--AIDS | Antiretroviral agents | Human immunodeficiency virus--HIV | Collaboration | Adults | AIDS | HIV | Acquired immune deficiency syndrome | Human immunodeficiency virus
HIV-2-INFECTED INDIVIDUALS | INTERNATIONAL COLLABORATION | RALTEGRAVIR | MULTIDISCIPLINARY SCIENCES | IMMUNOLOGICAL RESPONSE | INFECTION | DRUG-RESISTANCE | TYPE-1 HIV-1 | DIFFERENTIATION | INHIBITORS | TO-CHILD TRANSMISSION | Africa, Western - epidemiology | HIV-1 - isolation & purification | HIV-2 - isolation & purification | HIV Infections - virology | Humans | Middle Aged | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | Male | Cohort Studies | Infection | Antiviral agents | Highly active antiretroviral therapy | Analysis | HIV (Viruses) | Health aspects | Evidence-based medicine | Epidemiology | Medical research | Antiretroviral drugs | Therapy | Clinical trials | Infections | Medical diagnosis | Patients | Antiretroviral therapy | CD4 antigen | Acquired immune deficiency syndrome--AIDS | Antiretroviral agents | Human immunodeficiency virus--HIV | Collaboration | Adults | AIDS | HIV | Acquired immune deficiency syndrome | Human immunodeficiency virus
Journal Article
AIDS, ISSN 0269-9370, 2014, Volume 28, Issue 8, pp. 1161 - 1169
Objective: To assess the virological response, genotypic resistance profiles, and antiretroviral plasma concentrations in HIV-2 antiretroviral-treated...
Côte d'Ivoire | HIV-2 | Plasma drug concentrations | Antiretroviral resistance | VIRAL LOAD | INFECTIOUS DISEASES | Cote d'Ivoire | IMMUNOLOGY | PROTEASE INHIBITORS | HIV-2-INFECTED PATIENTS | SENEGAL IMPLICATIONS | IN-VITRO | antiretroviral resistance | REVERSE-TRANSCRIPTASE INHIBITORS | VIROLOGY | VITRO PHENOTYPIC SUSCEPTIBILITY | plasma drug concentrations | ANTIRETROVIRAL DRUG-RESISTANCE | HIV-2 INFECTION | IMMUNODEFICIENCY-VIRUS TYPE-2 | Anti-Retroviral Agents - therapeutic use | Cross-Sectional Studies | HIV Infections - genetics | Humans | Middle Aged | Genotype | Male | Treatment Outcome | Mutation - genetics | Viral Load | Sequence Analysis, RNA - methods | Drug Resistance, Viral - genetics | Adult | Female | HIV Infections - drug therapy | HIV-2 - genetics | Anti-Retroviral Agents - blood | Patient Compliance | Chromatography, Liquid - methods | Tandem Mass Spectrometry - methods | Côte d’Ivoire
Côte d'Ivoire | HIV-2 | Plasma drug concentrations | Antiretroviral resistance | VIRAL LOAD | INFECTIOUS DISEASES | Cote d'Ivoire | IMMUNOLOGY | PROTEASE INHIBITORS | HIV-2-INFECTED PATIENTS | SENEGAL IMPLICATIONS | IN-VITRO | antiretroviral resistance | REVERSE-TRANSCRIPTASE INHIBITORS | VIROLOGY | VITRO PHENOTYPIC SUSCEPTIBILITY | plasma drug concentrations | ANTIRETROVIRAL DRUG-RESISTANCE | HIV-2 INFECTION | IMMUNODEFICIENCY-VIRUS TYPE-2 | Anti-Retroviral Agents - therapeutic use | Cross-Sectional Studies | HIV Infections - genetics | Humans | Middle Aged | Genotype | Male | Treatment Outcome | Mutation - genetics | Viral Load | Sequence Analysis, RNA - methods | Drug Resistance, Viral - genetics | Adult | Female | HIV Infections - drug therapy | HIV-2 - genetics | Anti-Retroviral Agents - blood | Patient Compliance | Chromatography, Liquid - methods | Tandem Mass Spectrometry - methods | Côte d’Ivoire
Journal Article
BMC Medicine, ISSN 1741-7015, 04/2017, Volume 15, Issue 1, p. 85
Background: The 2016 World Health Organization guidelines recommend all children <3 years start antiretroviral therapy (ART) on protease inhibitor-based...
HIV | Protease inhibitors | Randomised clinical trial | Virological outcomes | Early antiretroviral treatment | Lopinavir | Africa | Treatment simplification | Infants | Efavirenz | MORTALITY | DIAGNOSIS | OPPORTUNITIES | NEVIRAPINE | PROTEASE INHIBITOR | MEDICINE, GENERAL & INTERNAL | 1ST-LINE ANTIRETROVIRAL THERAPY | RESISTANCE | EXPOSURE | Dideoxynucleosides - administration & dosage | HIV-1 | Lamivudine - administration & dosage | Benzoxazines - administration & dosage | Ritonavir - administration & dosage | HIV Infections - virology | Humans | Cote d'Ivoire | Child, Preschool | Genotype | Infant | Male | Treatment Outcome | Reverse Transcriptase Inhibitors - administration & dosage | Anti-HIV Agents - administration & dosage | Burkina Faso | Lopinavir - administration & dosage | Female | HIV Infections - drug therapy | Drug Therapy, Combination | Viral Load - drug effects | Drug Combinations | Infant, Newborn | Low income groups | Drugs | Antiretroviral drugs | Therapy | Simplification | Statistical analysis | Drug resistance | Statistical tests | Syrup | Antiretroviral therapy | Confidence intervals | Randomization | Tuberculosis | Protease | Human immunodeficiency virus--HIV | Mutation | Children | Refrigeration | Zidovudine | Age
HIV | Protease inhibitors | Randomised clinical trial | Virological outcomes | Early antiretroviral treatment | Lopinavir | Africa | Treatment simplification | Infants | Efavirenz | MORTALITY | DIAGNOSIS | OPPORTUNITIES | NEVIRAPINE | PROTEASE INHIBITOR | MEDICINE, GENERAL & INTERNAL | 1ST-LINE ANTIRETROVIRAL THERAPY | RESISTANCE | EXPOSURE | Dideoxynucleosides - administration & dosage | HIV-1 | Lamivudine - administration & dosage | Benzoxazines - administration & dosage | Ritonavir - administration & dosage | HIV Infections - virology | Humans | Cote d'Ivoire | Child, Preschool | Genotype | Infant | Male | Treatment Outcome | Reverse Transcriptase Inhibitors - administration & dosage | Anti-HIV Agents - administration & dosage | Burkina Faso | Lopinavir - administration & dosage | Female | HIV Infections - drug therapy | Drug Therapy, Combination | Viral Load - drug effects | Drug Combinations | Infant, Newborn | Low income groups | Drugs | Antiretroviral drugs | Therapy | Simplification | Statistical analysis | Drug resistance | Statistical tests | Syrup | Antiretroviral therapy | Confidence intervals | Randomization | Tuberculosis | Protease | Human immunodeficiency virus--HIV | Mutation | Children | Refrigeration | Zidovudine | Age
Journal Article
AIDS, ISSN 0269-9370, 07/2014, Volume 28, Issue 11, pp. 1645 - 1655
Objective: We describe the association between age at antiretroviral therapy (ART) initiation and 24-month CD4(+) cell response in West African HIV-infected...
Immune reconstitution | Children | HIV | West Africa | Antiretroviral therapy | MORTALITY | INFECTIOUS DISEASES | ABIDJAN | COTE-DIVOIRE | antiretroviral therapy | CD4(+) cell | immune reconstitution | IMMUNOLOGY | VIROLOGY | MORBIDITY | children | CD4 CELL RESPONSE | OUTCOMES | PROGRAM | west Africa | Anti-Retroviral Agents - therapeutic use | Age Factors | Humans | Child, Preschool | Infant | Male | Treatment Outcome | CD4 Lymphocyte Count | CD4-Positive T-Lymphocytes - immunology | HIV Infections - immunology | Sex Factors | Female | HIV Infections - drug therapy | Child | Africa, Western | Life Sciences | Santé publique et épidémiologie
Immune reconstitution | Children | HIV | West Africa | Antiretroviral therapy | MORTALITY | INFECTIOUS DISEASES | ABIDJAN | COTE-DIVOIRE | antiretroviral therapy | CD4(+) cell | immune reconstitution | IMMUNOLOGY | VIROLOGY | MORBIDITY | children | CD4 CELL RESPONSE | OUTCOMES | PROGRAM | west Africa | Anti-Retroviral Agents - therapeutic use | Age Factors | Humans | Child, Preschool | Infant | Male | Treatment Outcome | CD4 Lymphocyte Count | CD4-Positive T-Lymphocytes - immunology | HIV Infections - immunology | Sex Factors | Female | HIV Infections - drug therapy | Child | Africa, Western | Life Sciences | Santé publique et épidémiologie
Journal Article
BMC Infectious Diseases, 08/2015, Volume 15, Issue 1, p. 317
Background: Cotrimoxazole prophylaxis has an antimalarial effect which could have an additional protective effect against malaria in HIV-infected children on...
Cotrimoxazole | Children | HIV | Malaria | Antiretroviral therapy | Africa | MORTALITY | INFECTIOUS DISEASES | HIV-1-INFECTED ADULTS | UGANDA | IMPACT | IMMUNOSUPPRESSION | INSECTICIDE-TREATED BEDNETS | DISEASE | PROGRAM | TRIMETHOPRIM-SULFAMETHOXAZOLE | Prospective Studies | Follow-Up Studies | Humans | Child, Preschool | Male | Antimalarials - therapeutic use | Cote d'Ivoire - epidemiology | Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use | Incidence | Regression Analysis | Malaria - epidemiology | HIV Infections - complications | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | Malaria - complications | Malaria - drug therapy | Child | Cohort Studies
Cotrimoxazole | Children | HIV | Malaria | Antiretroviral therapy | Africa | MORTALITY | INFECTIOUS DISEASES | HIV-1-INFECTED ADULTS | UGANDA | IMPACT | IMMUNOSUPPRESSION | INSECTICIDE-TREATED BEDNETS | DISEASE | PROGRAM | TRIMETHOPRIM-SULFAMETHOXAZOLE | Prospective Studies | Follow-Up Studies | Humans | Child, Preschool | Male | Antimalarials - therapeutic use | Cote d'Ivoire - epidemiology | Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use | Incidence | Regression Analysis | Malaria - epidemiology | HIV Infections - complications | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | Malaria - complications | Malaria - drug therapy | Child | Cohort Studies
Journal Article
Journal of the International AIDS Society, ISSN 1758-2652, 01/2016, Volume 19, Issue 1, pp. 20044 - n/a
Introduction Response to antiretroviral therapy (ART) among individuals infected with HIV‐2 is poorly described. We compared the immunological response among...
HIV‐2 | linear mixed models | immunological response | antiretroviral treatment | West Africa | Linear mixed models | HIV-2 | Immunological response | Antiretroviral treatment | INFECTIOUS DISEASES | REVERSE-TRANSCRIPTASE | SUSCEPTIBILITY | DRUG-RESISTANCE | PREVALENCE | IMMUNOLOGY | EMERGENCE | PROTEASE INHIBITORS | SENEGAL IMPLICATIONS | ACTIVE ANTIRETROVIRAL THERAPY | HIV-2 INFECTION | LOPINAVIR/RITONAVIR | HIV Infections - immunology | Prospective Studies | Humans | Middle Aged | Adult | Female | HIV Infections - drug therapy | Male | CD4 Lymphocyte Count | Cohort Studies | Highly active antiretroviral therapy | Immune response | Protease inhibitors | Analysis | HIV (Viruses) | Drug therapy | Health aspects | Epidemiology | Antiretroviral drugs | Immunology | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Collaboration | Questionnaires | Infections | Family medical history | Data bases
HIV‐2 | linear mixed models | immunological response | antiretroviral treatment | West Africa | Linear mixed models | HIV-2 | Immunological response | Antiretroviral treatment | INFECTIOUS DISEASES | REVERSE-TRANSCRIPTASE | SUSCEPTIBILITY | DRUG-RESISTANCE | PREVALENCE | IMMUNOLOGY | EMERGENCE | PROTEASE INHIBITORS | SENEGAL IMPLICATIONS | ACTIVE ANTIRETROVIRAL THERAPY | HIV-2 INFECTION | LOPINAVIR/RITONAVIR | HIV Infections - immunology | Prospective Studies | Humans | Middle Aged | Adult | Female | HIV Infections - drug therapy | Male | CD4 Lymphocyte Count | Cohort Studies | Highly active antiretroviral therapy | Immune response | Protease inhibitors | Analysis | HIV (Viruses) | Drug therapy | Health aspects | Epidemiology | Antiretroviral drugs | Immunology | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Collaboration | Questionnaires | Infections | Family medical history | Data bases
Journal Article